Arrowhead Pharmaceuticals (NASDAQ:ARWR) used its presentation at the JPMorgan Healthcare Conference to highlight a newly launched RNA interference (RNAi) therapy, a broad clinical-stage pipeline, and ...

The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...

Arrowhead’s candidate, called ARO-INHBE, plus Zepbound, doubled weight loss and tripled reductions in visceral fat, total fat ...

Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

Arrowhead Pharmaceuticals said Tuesday that its gene-silencing drug candidate nearly doubled four-month weight loss ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) shared initial interim clinical results from two RNA interference (RNAi) obesity ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated efficacy ...

World RNAi Market 2010Contract service = outsourced research/target validation projects Total = Projected worldwide RNAi revenues for 2010, in US dollars Source: Frost & SullivanScientists hunger for ...

Nearly 1.3 billion adults around the world have clinically high blood pressure, many of whom may be unaware that they are living with this condition. Nearly 1.3 billion adults around the world have ...

Researchers can transfect other types of RNA molecules as well. Messenger RNA transfection enables direct analyses of RNA function because the transfected messages can be expressed in the absence of ...